SAN DIEGO, Dec. 15, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, today celebrated continued positive reception by
the industry and collaborators of its exVive3DTM Human
Liver Tissue. The product, which was made widely available in
full commercial release on November
18, has been recognized as groundbreaking in the field,
resulting in several awards for innovation.
Most recently, on December 4,
Organovo's exVive3DTM Human Liver Tissue was selected by
a panel of industry judges as a CONNECT 2014 Most Innovative
Product. CONNECT is a San
Diego innovation organization, with membership from over 120
firms and universities, that catalyzes the creation of innovative
technology and life sciences products in San Diego. The
exVive3DTM Human Liver was selected as the winner from a
highly innovative set of competitive research tools and diagnostic
products.
Also this month, the exVive3DTM Human Liver Tissue
was selected by a separate panel of judges from industry and
academia as one of the Top 10 Innovations of 2014 by The
Scientist magazine, a widely read and well respected news
outlet for life science researchers.
Earlier this year Organovo's liver tissue was also named a
Silver award winner in the life science space at the 2014 Edison
Awards and the Company was named a 2015 Technology Pioneer
by the World Economic Forum.
"Organovo's first-in-class tissue has been very well received by
the scientific community," commented Organovo Chief Executive
Officer Keith Murphy. "Our
current data provides ample evidence for customers to engage in our
commercial research services, and we have been honored by a number
of awards acknowledging the innovative nature of our product.
We look forward to continuing to expand the impact and uptake of
the exVive3DTM Human Liver Tissue, along with extending
our offering with other equally innovative tissue types."
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio offering, a
3D Human Liver Tissue for use in Toxicology and other preclinical
drug testing. Additional products, including a 3D Kidney Model, are
in development with anticipated release for use in the latter half
of calendar year 2016. The company also actively conducts early
research on specific tissues for therapeutic use in direct surgical
applications. In addition to numerous scientific publications, the
Company's technology has been featured in The Wall Street Journal,
Time Magazine, The Economist, and numerous others. Organovo is
changing the shape of medical research and practice. Learn more at
www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed
with the SEC on November 7, 2014, as
well as our other filings with the SEC. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-celebrates-a-positive-2014-reception-of-its-exvive3dtm-human-liver-tissue-product-300009373.html
SOURCE Organovo Holdings, Inc.